Optimizing the safety of antibody–drug conjugates for patients with solid tumours
P Tarantino, B Ricciuti, SM Pradhan… - Nature reviews Clinical …, 2023 - nature.com
Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …
have enabled major advances that have reshaped the treatment of several advanced-stage …
[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
[HTML][HTML] Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform
L Conilh, G Fournet, E Fourmaux, A Murcia, EL Matera… - Pharmaceuticals, 2021 - mdpi.com
We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …
[HTML][HTML] The challenges of treating patients with breast cancer and obesity
A LeVee, J Mortimer - Cancers, 2023 - mdpi.com
Simple Summary Obesity is a poor prognostic factor for patients with breast cancer, resulting
in increased risk of recurrence and death due to breast cancer. Obesity can affect both the …
in increased risk of recurrence and death due to breast cancer. Obesity can affect both the …
Exposure‐response relationships in patients with HER2‐positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan
O Yin, H Iwata, CC Lin, K Tamura… - Clinical …, 2021 - Wiley Online Library
Trastuzumab deruxtecan (T‐DXd) is a HER2‐targeting antibody‐drug conjugate composed
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database
Z Ma, Y Zhang, M Zhu, L Feng, Y Zhang… - Expert review of clinical …, 2022 - Taylor & Francis
Background Interstitial lung disease (ILD) events associated with anti-human epidermal
growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide …
growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide …
[HTML][HTML] Trastuzumab deruxtecan in breast cancer
M Martín, A Pandiella, E Vargas-Castrillón… - Critical Reviews in …, 2024 - Elsevier
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a
humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody …
humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody …
[HTML][HTML] Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma
Y Tanaka, T Ito, Y Kaku-Ito, K Tanegashima… - Cell Death …, 2023 - nature.com
Acral melanoma (AM) is a rare, life-threatening skin cancer. Since AM bears unique
features, existing therapies for other types of malignant melanomas have limited effects and …
features, existing therapies for other types of malignant melanomas have limited effects and …
The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
L Kou, X Chen, X Xie, Q Wen, J Li… - Japanese Journal of …, 2023 - academic.oup.com
Objective We performed a meta-analysis to assess the efficacy and safety of T-DXd in the
treatment of HER2-expressing solid tumours. Methods We systematically searched PubMed …
treatment of HER2-expressing solid tumours. Methods We systematically searched PubMed …
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook
Introduction Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …